Finance

Lists
CONCORDBIO:NSE
Concord Biotech Ltd
₹1,426.30
+4.49%
(+61.30) 1D
Aug 10, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for CONCORDBIO...
Open
₹1,372.10
High
₹1,437.00
Low
₹1,372.10
Mkt. cap
149.21B
Avg. vol.
0.00
Volume
360.09K
Dividend
0.53%
Quarterly dividend
₹1.89
Ex-dividend date
Jul 24, 2026
P/E ratio
54.21
52-wk high
₹1,801.90
52-wk low
₹987.00
EPS
₹26.31
No. of employees
2K
Open
₹1,372.10
High
₹1,437.00
Low
₹1,372.10
Mkt. cap
149.21B
Avg. vol.
0.00
Volume
360.09K
Dividend
0.53%
Quarterly dividend
₹1.89
Ex-dividend date
Jul 24, 2026
P/E ratio
54.21
52-wk high
₹1,801.90
52-wk low
₹987.00
EPS
₹26.31
No. of employees
2K
Profile
Concord Biotech Limited is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation-based biopharmaceutical active pharmaceutical ingredients sold worldwide. It manufactures biopharmaceutical products across therapy segments such as immunosuppressant, oncology, antifungal, antibacterial and anthelmintic. It has two manufacturing facilities–at Dholka near Ahmedabad, which is approved by USFDA, and at Limbasi in Kheda district. Wikipedia
About Concord Biotech Ltd
CEO-
Employees1.62K
Founded2000
Headquarters-
SectorPharmaceutical industry
Websiteconcordbiotech.com
Last report
Aug 3, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
₹5.52 / ₹5.60
-1.43%miss
Revenue / Est. (INR)
2.57B / 2.45B
+5.05%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.47B
2.78B
3.26B
2.57B
Cost of goods sold
775.44M
941.71M
1.32B
890.11M
Cost of revenue
775.44M
941.71M
1.32B
890.11M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
444.56M
467.81M
477.71M
436.38M
Operating expense
994.14M
1.03B
837.11M
1.04B
Total operating expenses
1.77B
1.98B
2.16B
1.93B
Operating income
701.00M
802.34M
1.10B
642.76M
Other non operating income
133.52M
99.76M
-356.29M
128.26M
EBT including unusual items
856.84M
861.56M
1.14B
783.43M
EBT excluding unusual items
856.84M
894.31M
929.35M
783.43M
Income tax expense
226.21M
225.14M
256.08M
206.46M
Effective tax rate
26.40%
26.13%
22.45%
26.35%
Other operating expenses
365.67M
378.34M
163.96M
424.64M
Net income
635.81M
644.77M
887.90M
585.26M
Net profit margin
25.74%
23.21%
27.23%
22.73%
Earnings per share
6.03
6.31
8.46
5.52
Interest and investment income
-
-
24.63M
-
Interest expense
-591.00K
-815.00K
-840.00K
-364.00K
Net interest expenses
-591.00K
-815.00K
23.79M
-364.00K
Depreciation and amortization charges
183.92M
187.47M
195.44M
181.00M
EBITDA
881.84M
933.85M
1.28B
824.23M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps